Vifor Pharma announces Abbas Hussain as upcoming CEO

– SWITZERLAND, St. Gallen –  Vifor Pharma Group (SWX: VIFN) today announced the appointment of Abbas Hussain as CEO, effective on 16 August 2021.

“We are delighted that Abbas Hussain, an experienced and entrepreneurial leader, will take over the helm of Vifor Pharma. Abbas Hussain brings over 30 years of track record at an international level in the healthcare sector, and also an impressive experience across the pharmaceutical value chain in both mature and emerging markets. His professional background makes him ideally suited to further drive Vifor Pharma’s growth.” said Board chairman, Jacques Theurillat.

He added: “On behalf of the Board of Directors, I would like to thank Stefan Schulze for his commitment to Vifor Pharma over the past seven years. He has made a significant contribution to the strong market position of the Vifor Pharma Group. We wish him all the best for the future.”

About Abbas Hussain

Abbas Hussain, a British citizen, has a successful and international career of more than 30 years as an executive in the healthcare sector. From 2008 to 2017, Abbas Hussain held various leadership positions for the British pharmaceutical group GlaxoSmithKline, most recently as Global President of Pharmaceuticals and Vaccines for five years. Before that, he worked for 20 years for the U.S. pharmaceutical group Eli Lilly, holding management positions at sites in the US, Europe, Asia, and Australia.

In recent years, he has contributed his experience as an independent member of the boards of directors of major pharmaceutical, biotech, and medical device companies, such as Teva Pharmaceuticals, CSL, and Cochlear. He has also acted as an advisor to private equity and venture capital firms focused on the healthcare sector.

Abbas Hussain holds a Bachelor of Science in Medicinal and Pharmaceutical Chemistry from Loughborough Institute of Technology (UK), graduated from Duke University Fuqua Executive Business School (North Carolina, USA), and is a graduate of the Stanford Executive Program at Stanford University (California, USA).

About Vifor Pharma Group

Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology, and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures, and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).

For more information: https://www.viforpharma.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.